BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.041095
+0.002695 (7.02%)
At close: Sep 28, 2026
BioXcel Therapeutics Employees
BioXcel Therapeutics had 29 employees as of December 31, 2025. The number of employees decreased by 8 or -21.62% compared to the previous year.
Employees
29
Change (1Y)
-8
Growth (1Y)
-21.62%
Revenue / Employee
$25,586
Profits / Employee
-$2,443,448
Market Cap
1.29M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | -8 | -21.62% |
| Dec 31, 2024 | 37 | -37 | -50.00% |
| Dec 31, 2023 | 74 | -109 | -59.56% |
| Dec 31, 2022 | 183 | 94 | 105.62% |
| Dec 31, 2021 | 89 | 39 | 78.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
BioXcel Therapeutics News
- 4 weeks ago - BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals - GlobeNewsWire
- 4 weeks ago - Biopharma firm BioXcel Therapeutics files for bankruptcy in US - Reuters
- 4 months ago - BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - GlobeNewsWire
- 5 months ago - Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 5 months ago - BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - GlobeNewsWire
- 6 months ago - BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - GlobeNewsWire